Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Savara Inc. (NASDAQ:SVRA) saw unusually-high trading volume on Friday . Approximately 1,314,910 shares were traded during trading, a decline of 8% from the previous session’s volume of 1,435,789 shares.The stock last traded at $6.4250 and had previously closed at $6.37.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SVRA. HC Wainwright raised their price objective on shares of Savara from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. JMP Securities lifted their price objective on Savara from $8.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 23rd. Citigroup reiterated an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Lifesci Capital upgraded Savara to a “strong-buy” rating in a research report on Tuesday, October 14th. Finally, Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.29.

Savara Trading Up 2.0%

The business has a 50 day simple moving average of $4.34 and a 200-day simple moving average of $3.30. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -12.26 and a beta of 0.23. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, equities analysts expect that Savara Inc. will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Savara

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. boosted its stake in Savara by 82.9% in the 1st quarter. Invesco Ltd. now owns 89,258 shares of the company’s stock worth $247,000 after purchasing an additional 40,461 shares during the period. Nuveen LLC bought a new stake in shares of Savara in the first quarter valued at about $1,067,000. Brooklyn Investment Group acquired a new position in shares of Savara during the first quarter worth about $65,000. EntryPoint Capital LLC boosted its position in shares of Savara by 75.9% during the first quarter. EntryPoint Capital LLC now owns 181,655 shares of the company’s stock worth $503,000 after buying an additional 78,367 shares during the period. Finally, Jump Financial LLC grew its holdings in shares of Savara by 214.1% during the first quarter. Jump Financial LLC now owns 65,200 shares of the company’s stock worth $181,000 after buying an additional 44,445 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.